The demo achieved each its primary endpoints, with semaglutide 2.four mg demonstrating statistically major and excellent advancements in liver fibrosis without having worsening of steatohepatitis, and also resolution of steatohepatitis without worsening of liver fibrosis in individuals with MASH compared to placebo.1These highlights will not contai